{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Horse+Anti-thymocyte+Globulin",
    "query": {
      "intervention": "Horse Anti-thymocyte Globulin"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 33,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Horse+Anti-thymocyte+Globulin&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T04:24:55.558Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02102854",
      "title": "Single Dose rATG for Renal Allograft Rejection",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acute (Cellular) Renal Allograft Rejection"
      ],
      "interventions": [
        {
          "name": "rATG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Methodist Hospital Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 30,
      "start_date": "2014-03",
      "completion_date": "2021-10",
      "has_results": false,
      "last_update_posted_date": "2020-09-03",
      "last_synced_at": "2026-10-08T04:24:55.558Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02102854"
    },
    {
      "nct_id": "NCT01019876",
      "title": "Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Bone Marrow Failure",
        "Osteopetrosis",
        "Fanconi Anemia",
        "Severe Combined Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Rabbit Anti-thymocyte Globulin",
          "type": "DRUG"
        },
        {
          "name": "Horse Anti-thymocyte Globulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": 38,
      "start_date": "2002-09",
      "completion_date": "2021-09-07",
      "has_results": false,
      "last_update_posted_date": "2024-10-31",
      "last_synced_at": "2026-10-08T04:24:55.558Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01019876"
    },
    {
      "nct_id": "NCT06430788",
      "title": "A Study of Emapalumab for Pediatric Aplastic Anemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Aplastic Anemia",
        "Cytopenia",
        "Hypocellular Marrow"
      ],
      "interventions": [
        {
          "name": "Emapalumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "0 Years to 25 Years"
      },
      "enrollment_count": 35,
      "start_date": "2024-05-21",
      "completion_date": "2029-05-21",
      "has_results": false,
      "last_update_posted_date": "2025-12-17",
      "last_synced_at": "2026-10-08T04:24:55.558Z",
      "location_count": 6,
      "location_summary": "New York, New York • Cincinnati, Ohio • Philadelphia, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06430788"
    },
    {
      "nct_id": "NCT02694770",
      "title": "A Study Evaluating the Efficacy and Safety of Neihulizumab vs \"Conventional Treatment\" to Treat Sr-aGvHD",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation"
      ],
      "interventions": [
        {
          "name": "Neihulizumab Treatment",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Conventional Treatment",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AbGenomics B.V Taiwan Branch",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2016-07",
      "completion_date": "2018-02",
      "has_results": false,
      "last_update_posted_date": "2016-04-25",
      "last_synced_at": "2026-10-08T04:24:55.558Z",
      "location_count": 2,
      "location_summary": "Houston, Texas • Seattle, Washington",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02694770"
    },
    {
      "nct_id": "NCT02845596",
      "title": "Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Severe Aplastic Anemia"
      ],
      "interventions": [
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Matched Unrelated Donor Hematopoietic Stem Cell Transplant",
          "type": "PROCEDURE"
        },
        {
          "name": "horse anti-thymocyte globulin (ATG)",
          "type": "DRUG"
        },
        {
          "name": "rabbit anti-thymocyte globulin (ATG)",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "fludarabine",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "low-dose total body irradiation (TBI)",
          "type": "RADIATION"
        },
        {
          "name": "Immunosuppressive Therapy (IST)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Michael Pulsipher",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "Up to 25 Years"
      },
      "enrollment_count": 40,
      "start_date": "2016-08",
      "completion_date": "2023-07-19",
      "has_results": false,
      "last_update_posted_date": "2025-05-11",
      "last_synced_at": "2026-10-08T04:24:55.558Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02845596"
    },
    {
      "nct_id": "NCT03663933",
      "title": "Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoproliferative Disorders",
        "Autoimmune Lymphoproliferative",
        "Primary T-cell Immunodeficiency Disorders",
        "Immune System Diseases",
        "Common Variable Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "e-ATG",
          "type": "DRUG"
        },
        {
          "name": "Immunosuppression Only Conditioning",
          "type": "PROCEDURE"
        },
        {
          "name": "Reduced Intensity Conditioning",
          "type": "PROCEDURE"
        },
        {
          "name": "GVHD Prophylaxis",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic HSC",
          "type": "PROCEDURE"
        },
        {
          "name": "Bisulfan",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "MMF",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Pentostatin",
          "type": "DRUG"
        },
        {
          "name": "PFTs",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "DEXA",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Bone Marrow Aspirate & Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "EKG",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "2D ECHO",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "4 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2018-09-04",
      "completion_date": "2030-04-03",
      "has_results": true,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-10-08T04:24:55.558Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03663933"
    },
    {
      "nct_id": "NCT04862221",
      "title": "TReatment for ImmUne Mediated PathopHysiology",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Liver Failure",
        "Fulminant Hepatic Failure",
        "Hepatic Encephalopathy",
        "Acute Liver Injury",
        "Immune Dysregulation"
      ],
      "interventions": [
        {
          "name": "High-dose methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Equine anti-thymocyte globulin",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone",
          "type": "DRUG"
        },
        {
          "name": "Placebo for prednisolone",
          "type": "DRUG"
        },
        {
          "name": "Placebo for infusions",
          "type": "DRUG"
        },
        {
          "name": "Diphenhydramine",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "1 Year to 18 Years"
      },
      "enrollment_count": 44,
      "start_date": "2022-02-09",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-10-08T04:24:55.558Z",
      "location_count": 17,
      "location_summary": "Los Angeles, California • Palo Alto, California • San Diego, California + 14 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04862221"
    },
    {
      "nct_id": "NCT07001254",
      "title": "UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Aplastic Anemia"
      ],
      "interventions": [
        {
          "name": "Romiplostim",
          "type": "DRUG"
        },
        {
          "name": "Immunosuppressive therapy (IST)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Anjali Sharathkumar",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": 15,
      "start_date": "2026-08-01",
      "completion_date": "2031-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-12-19",
      "last_synced_at": "2026-10-08T04:24:55.558Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07001254"
    },
    {
      "nct_id": "NCT00305682",
      "title": "Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "umbilical cord blood transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "total body irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "Up to 75 Years"
      },
      "enrollment_count": 295,
      "start_date": "2005-06",
      "completion_date": "2019-12-12",
      "has_results": true,
      "last_update_posted_date": "2020-11-19",
      "last_synced_at": "2026-10-08T04:24:55.558Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00305682"
    },
    {
      "nct_id": "NCT03025698",
      "title": "A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Aplastic Anemia"
      ],
      "interventions": [
        {
          "name": "Eltrombopag",
          "type": "DRUG"
        },
        {
          "name": "hATG",
          "type": "DRUG"
        },
        {
          "name": "CsA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "1 Year to 18 Years"
      },
      "enrollment_count": 51,
      "start_date": "2017-09-30",
      "completion_date": "2025-01-27",
      "has_results": true,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-10-08T04:24:55.558Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Aurora, Colorado + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03025698"
    }
  ]
}